Hyperparathyroidism Treatment market will grow at highest pace owing to increasing incidence of hyperparathyroidism

Hyperparathyroidism Treatment market will grow at highest pace owing to increasing incidence of hyperparathyroidism

Hyperparathyroidism refers to a condition involving overactive parathyroid glands causing elevated blood calcium levels. The parathyroid glands are located in the neck and regulate the amount of calcium and phosphorus in the blood. Hyperparathyroidism causes the parathyroid glands to produce excess parathyroid hormone leading to excessive calcium resorption and mobilization from the bones into the bloodstream. The major symptoms of hyperparathyroidism include kidney stones, bone loss, fatigue, weakness, memory problems and mood changes. Treatment for hyperparathyroidism depends on the severity and persistence of symptoms, and generally includes surgery or medication. Surgery to remove the overactive parathyroid gland is considered the only cure for hyperparathyroidism. Medications such as bisphosphonates, calcimimetics, and estrogen/selective estrogen receptor modulators are used to manage symptoms in some cases or postpone surgery.

The Global Hyperparathyroidism Treatment Market is estimated to be valued at USD 780.1 Mn in 2024 and is expected to reach USD 991.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031.

Key Takeaways
Key players operating in the hyperparathyroidism treatment are AbbVie, Amgen, Entera Bio, Teva Pharmaceuticals, GlaxoSmithKline.

Growing aging population driving the prevalence of hyperparathyroidism and increasing awareness about this condition are fueling the Hyperparathyroidism Treatment Market Demand hyperparathyroidism treatment.

Technological advancements in minimally invasive surgical procedures for hyperparathyroidism such as focused parathyroidectomy aid recovery and offer low complication rates.

Market Trends
Increasing adoption of bisphosphonates - Bisphosphonates such as alendronate and risedronate are major treatment choices for asymptomatic hyperparathyroidism.
Rising popularity of calcimimetics - Calcium-sensing receptor agonists known as calcimimetics offer an alternative to parathyroidectomy for select groups of patients.

Market Opportunities
Untapped potential in developing regions - Low awareness and accessibility to treatment in developing countries provide major opportunities.
Novel therapies in pipeline - Emerging drugs targeting PTH, calcium-sensing receptors and calcium transport hold promise to change future treatment landscape.

Impact of COVID-19 on Hyperparathyroidism Treatment Market
The COVID-19 pandemic has impacted the growth of the hyperparathyroidism treatment market. During the initial lockdown phases imposed across various countries, non-essential surgeries including hyperparathyroidism treatment procedures were postponed. This led to a decline in the number of surgical procedures performed for hyperparathyroidism treatment. However, virtual consultations between endocrinologists and patients increased as people sought medical advice from home.

With restrictions now being lifted gradually, the market is expected to witness steady growth as the number of surgeries being conducted rises. However, available hospital beds, post-surgery care facilities, surgical teams and stringent safety protocols are likely to hinder market growth to some extent in the near future. Drug manufacturers are focusing on ensuring stable supply chains and prioritizing production of drugs used for hyperparathyroidism treatment. The pandemic has highlighted the need for development of newer non-surgical treatment options and drugs with improved efficacy in controlling parathyroid hormone levels.

Geographically, North America dominates the hyperparathyroidism treatment market in terms of value. This is attributed to the high diagnosis and treatment rates in the region. According to various studies, the United States accounts for over 80% of the total procedures conducted annually worldwide to treat hyperparathyroidism. Within North America, the United States holds the major market share currently and is expected to remain the fastest growing regional market over the forecast period.

Impact of COVID-19 on Hyperparathyroidism Treatment Market
Asia Pacific is projected to be the fastest growing regional market for hyperparathyroidism treatment during 2020-2027. The rate of growth is anticipated to be highest in China and India. Rising diagnostic capabilities in these nations coupled with growing prevalence of hyperparathyroidism are driving the Asia Pacific market. Moreover, increasing penetration of private healthcare providers, medical tourists travels within the Asia Pacific region and launch of novel drugs are expected to fuel the regional market over the coming years. However, current pandemic may cause short term decline across Asian countries depending on the intensity of spread and duration of lockdowns imposed. Overall Asia Pacific is likely to regain lost growth momentum post COVID-19.

Get More Insights On- Hyperparathyroidism Treatment Market

Get This Report in Japanese Language: 副甲状腺機能亢進症治療市場

Get This Report in Korean Language: 부갑상선기능항진증 치료 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.

(https://www.linkedin.com/in/ravina-pandya-1a3984191)